Ipatasertib

Target: Ipatasertib targets all three AKT isoforms, AKT1, AKT2, and AKT3.

Mechanism of Action: Ipatasertib can be used as an ATP-competitive AKT-binding element for degrader design. In a PROTAC, the ipatasertib-derived ligand recognizes AKT, while an optimized linker connects it to an E3 ligase ligand. The degrader is intended to recruit AKT and the ligase simultaneously, forming a ternary complex that positions the kinase surface for ubiquitination. When complex stability and orientation are productive, AKT becomes polyubiquitinated and is removed by the ubiquitin-proteasome system, producing target depletion instead of only reversible pathway blockade. This establishes a testable protein-depletion mechanism for research assays.

• AKT Degrader PROTAC Design: Ipatasertib can serve as a kinase-binding warhead in PROTAC constructs to recruit E3 ligases and drive selective AKT pathway protein degradation. This approach enables functional interrogation of AKT signaling beyond inhibition, helping determine whether reduced AKT abundance produces distinct downstream effects in comparison with catalytic blockade.

• E3 Ligase Recruitment Optimization: Incorporating Ipatasertib into PROTAC scaffolds supports systematic testing of different E3 ligase recruiters to maximize ternary complex formation and degradation efficiency. Researchers can tune linker length, attachment sites, and overall geometry to enhance ubiquitination kinetics and achieve robust, target-dependent protein loss in relevant cellular models.

• Pathway Mechanism Studies: Ipatasertib-based PROTACs can be used to dissect AKT-driven survival and metabolism pathways by monitoring degradation-dependent changes in phosphorylation networks. Comparing degradation versus inhibition phenotypes clarifies whether AKT removal, rather than transient kinase suppression, better explains alterations in cell cycle progression, apoptosis markers, and stress response signaling.

• Resistance and Feedback Evaluation: Targeted degradation using an Ipatasertib warhead can help probe resistance mechanisms arising from compensatory signaling and feedback loops in AKT pathway networks. By degrading AKT isoforms or related nodes, PROTAC strategies can test whether sustained protein depletion mitigates adaptive reactivation that often limits inhibitor-only approaches.

Ipatasertib is a pan-AKT inhibitor with a non-ATP-competitive binding profile reported in chemical databases and literature records. Its piperazine-linked cyclopenta-pyrimidine scaffold and hydroxy/basic side-chain features make it a useful ligand candidate for AKT degrader exploration. This molecule is described in detail below.

Structure: The structure includes a chlorophenyl-substituted chiral propanone linked to a piperazine, a hydroxy-methyl cyclopenta[d]pyrimidine, and an isopropylamino substituent. The tertiary piperazine and secondary alcohol create polar regions for solubility and possible derivatization.

Reactivity: Linker installation for AKT PROTAC design should prioritize solvent-exposed positions on the piperazine or aminoalcohol side chain and avoid perturbing the cyclopenta-pyrimidine recognition element unless SAR data supports modification. PEG, alkyl, or amide-containing linkers may be paired with CRBN or VHL ligands, while linker flexibility and length should be systematically optimized to produce a stable AKT-E3 ternary complex.